Startups

The Association for Frontotemporal Degeneration
2700 Horizon Drive, Suite 120, King of Prussia, PA 19406, United States
The Association for Frontotemporal Degeneration (AFTD) is a US nonprofit public charity founded in2002 by Helen-Ann Comstock to support people affected by frontotemporal degeneration and advance research towards treatments and a cure. Its official tax return identifies EIN41-2073220, Pennsylvania organization, and Section501(c)(3) status. It is headquartered at2700 Horizon Drive, Suite120, King of Prussia, Pennsylvania19406. This is a neuroscience research and mission-related investment institution, rather than a commercial venture manager. AFTD's work combines scientific funding, research participation and engagement, medical education, support services and public advocacy. Its scientific interests span FTD biology, genetics, biomarkers, clinical studies and development of disease-modifying therapies. Its current scientific leadership includes Chief Scientific Officer Penny Dacks. Rachel Biblow became CEO in May2026, succeeding Susan L-J Dickinson; older documents naming Susan as CEO are historical. The current public professional directories publish51 staff,18 current directors and31 active external Medical Advisory Council members. External advisers are scoped advisory relationships rather than employees. Founder Helen-Ann Comstock's board service ended with her death on July30,2025. AFTD and the Alzheimer's Drug Discovery Foundation jointly established the Treat FTD programme in2016. Its current call supports relevant clinical trials through academic grants or biotechnology mission-related investments. Award ceilings, charitable income, programme budgets and fundraising goals are not LP fund closes or evidence of cash already paid. Biotechnology payments may depend on negotiated development and enrollment milestones. Treat FTD is recorded as a joint programme of its two institutions rather than a third duplicate cash investor. Vesper Bio announced a USD2.5million strategic mission-related investment from AFTD and ADDF through Treat FTD on November17,2025. Per-institution allocations and actual disbursement schedule are undisclosed. This funding relationship does not establish regulatory approval or proven clinical benefit of Vesper's investigational medicine. Exact company financing is source-qualified on the issuer record and is maintained separately from AFTD's charitable receipts. No commercial investment-fund ownership or institution-wide health status is inferred from its mission.
Founded 2002





































































































